

By Senator Stargel

22-00467E-18

20181128\_\_

1                   A bill to be entitled  
2       An act relating to pharmacy; amending s. 465.003,  
3       F.S.; defining and redefining terms; amending s.  
4       465.004, F.S.; revising the membership of the Board of  
5       Pharmacy; amending s. 465.019, F.S.; establishing  
6       Class III institutional pharmacies; authorizing such  
7       pharmacies to dispense, compound, and fill  
8       prescriptions, prepare prepackaged drug products, and  
9       conduct other pharmaceutical services between certain  
10      entities under common control; defining the term  
11      "common control"; providing that the lawful dispensing  
12      and distribution of medicinal drugs by Class III  
13      institutional pharmacies is not considered wholesale  
14      distribution; requiring such pharmacies to maintain  
15      certain policies and procedures; conforming provisions  
16      to changes made by the act; amending s. 465.0252,  
17      F.S.; conforming a provision to changes made by the  
18      act; amending s. 499.003, F.S.; revising the  
19      definition of the term "prepackaged drug product";  
20      amending s. 499.01, F.S.; providing that a  
21      prescription drug repackager permit and a restricted  
22      prescription drug distributor permit are not required  
23      for the distribution of medicinal drugs or prepackaged  
24      drug products between entities under common control  
25      under certain circumstances; providing that a certain  
26      hospital is not required to hold a restricted  
27      prescription drug distributor permit under certain  
28      circumstances; deleting a provision exempting certain  
29      drug repackagers from specified permit requirements;

22-00467E-18

20181128\_\_

30 providing an effective date.

31  
32 Be It Enacted by the Legislature of the State of Florida:

33  
34 Section 1. Subsections (7) and (13) of section 465.003,  
35 Florida Statutes, are amended, and subsection (21) is added to  
36 that section, to read:

37 465.003 Definitions.—As used in this chapter, the term:

38 (7) "Institutional formulary system" means a method whereby  
39 the medical staff evaluates, appraises, and selects those  
40 medicinal drugs or proprietary preparations that ~~which~~ in the  
41 medical staff's clinical judgment are most useful in patient  
42 care, and that ~~which~~ are available for dispensing by a  
43 practicing pharmacist in a Class II or Class III institutional  
44 pharmacy.

45 (13) "Practice of the profession of pharmacy" includes  
46 compounding, dispensing, and consulting concerning contents,  
47 therapeutic values, and uses of any medicinal drug; consulting  
48 concerning therapeutic values and interactions of patent or  
49 proprietary preparations, whether pursuant to prescriptions or  
50 in the absence and entirely independent of such prescriptions or  
51 orders; and conducting other pharmaceutical services. For  
52 purposes of this subsection, "other pharmaceutical services"  
53 means the monitoring of the patient's drug therapy and assisting  
54 the patient in the management of his or her drug therapy, and  
55 includes review of the patient's drug therapy and communication  
56 with the patient's prescribing health care provider as licensed  
57 under chapter 458, chapter 459, chapter 461, or chapter 466, or  
58 similar statutory provision in another jurisdiction, or such

22-00467E-18

20181128\_\_

59 provider's agent or such other persons as specifically  
60 authorized by the patient, regarding the drug therapy. However,  
61 nothing in this subsection may be interpreted to permit an  
62 alteration of a prescriber's directions, the diagnosis or  
63 treatment of any disease, the initiation of any drug therapy,  
64 the practice of medicine, or the practice of osteopathic  
65 medicine, unless otherwise permitted by law. "Practice of the  
66 profession of pharmacy" also includes any other act, service,  
67 operation, research, or transaction incidental to, or forming a  
68 part of, any of the foregoing acts, requiring, involving, or  
69 employing the science or art of any branch of the pharmaceutical  
70 profession, study, or training, and shall expressly permit a  
71 pharmacist to transmit information from persons authorized to  
72 prescribe medicinal drugs to their patients. The practice of the  
73 profession of pharmacy also includes the administration of  
74 vaccines to adults pursuant to s. 465.189 and the preparation of  
75 prepackaged drug products in facilities holding Class III  
76 institutional pharmacy permits.

77 (21) "Central distribution facility" means a facility under  
78 common control with a hospital holding a Class III institutional  
79 pharmacy permit which may dispense, distribute, compound, or  
80 fill prescriptions for medicinal drugs; prepare prepackaged drug  
81 products; and conduct other pharmaceutical services.

82 Section 2. Subsection (2) of section 465.004, Florida  
83 Statutes, is amended to read:

84 465.004 Board of Pharmacy.—

85 (2) Seven members of the board must be licensed pharmacists  
86 who are residents of this state and who have been engaged in the  
87 practice of the profession of pharmacy in this state for at

22-00467E-18

20181128\_\_

88 least 4 years and, to the extent practicable, represent the  
89 various pharmacy practice settings. Of the pharmacist members,  
90 two must be currently engaged in the practice of pharmacy in a  
91 community pharmacy, two must be currently engaged in the  
92 practice of pharmacy in a Class II, ~~institutional pharmacy or a~~  
93 modified Class II, or Class III institutional pharmacy, and  
94 three must be pharmacists licensed in this state irrespective of  
95 practice setting. The remaining two members must be residents of  
96 the state who have never been licensed as pharmacists and who  
97 are in no way connected with the practice of the profession of  
98 pharmacy. No person may be appointed as a consumer member who is  
99 in any way connected with a drug manufacturer or wholesaler. At  
100 least one member of the board must be 60 years of age or older.  
101 The Governor shall appoint members to the board in accordance  
102 with this subsection as members' terms expire or as a vacancy  
103 occurs until the composition of the board complies with the  
104 requirements of this subsection.

105 Section 3. Subsections (4) and (6) of section 465.019,  
106 Florida Statutes, are amended, and paragraph (d) is added to  
107 subsection (2) of that section, to read:

108 465.019 Institutional pharmacies; permits.-

109 (2) The following classes of institutional pharmacies are  
110 established:

111 (d)1. "Class III institutional pharmacies" are those  
112 institutional pharmacies, including central distribution  
113 facilities, which are affiliated with a hospital and provide the  
114 same services as those authorized for Class II institutional  
115 pharmacies in subsection (6). Class III institutional pharmacies  
116 may dispense, distribute, compound, and fill prescriptions for

22-00467E-18

20181128\_\_

117 medicinal drugs; prepare prepackaged drug products; and conduct  
118 other pharmaceutical services for the affiliated hospital and  
119 entities under common control, each of which must be permitted  
120 under this chapter to possess medicinal drugs. A Class III  
121 institutional pharmacy may provide such medicinal drugs, drug  
122 products, and pharmaceutical services to an entity under common  
123 control that holds an active health care clinic establishment  
124 permit as described in s. 499.01(2)(r). For purposes of this  
125 chapter, the term "common control" means the power to direct or  
126 cause the direction of the management and policies of a person  
127 or an organization, whether by ownership of stock, voting  
128 rights, contract, or other means. The dispensing or distribution  
129 of a medicinal drug by a Class III institutional pharmacy  
130 pursuant to this section is not considered wholesale  
131 distribution as defined in s. 499.003.

132 2. A Class III institutional pharmacy shall maintain  
133 policies and procedures that identify or otherwise address:

134 a. The consultant pharmacist responsible for pharmaceutical  
135 services.

136 b. Safe practices for the preparation, dispensing,  
137 prepackaging, distribution, and transportation of medicinal  
138 drugs and prepackaged drug products.

139 c. Recordkeeping to monitor the movement, distribution, and  
140 transportation of medicinal drugs and prepackaged drug products.

141 d. Recordkeeping of pharmacy staff responsible for each  
142 step in the preparation, dispensing, prepackaging,  
143 transportation, and distribution of medicinal drugs and  
144 prepackaged drug products.

145 e. Medicinal drugs and prepackaged drug products that may

22-00467E-18

20181128\_\_

146 not be safely distributed among Class III institutional  
147 pharmacies.

148 (4) Medicinal drugs shall be dispensed in an institutional  
149 pharmacy to outpatients only when that institution has secured a  
150 community pharmacy permit from the department. However, an  
151 individual licensed to prescribe medicinal drugs in this state  
152 may dispense up to a 24-hour supply of a medicinal drug to any  
153 patient of an emergency department of a hospital that operates a  
154 Class II or Class III institutional pharmacy, provided that the  
155 physician treating the patient in such hospital's emergency  
156 department determines that the medicinal drug is warranted and  
157 that community pharmacy services are not readily accessible,  
158 geographically or otherwise, to the patient. Such dispensing  
159 from the emergency department must be in accordance with the  
160 procedures of the hospital. For any such patient for whom a  
161 medicinal drug is warranted for a period to exceed 24 hours, an  
162 individual licensed to prescribe such drug must dispense a 24-  
163 hour supply of such drug to the patient and must provide the  
164 patient with a prescription for such drug for use after the  
165 initial 24-hour period. The board may adopt rules necessary to  
166 carry out the provisions of this subsection.

167 (6) In a Class II or Class III institutional pharmacy, an  
168 institutional formulary system may be adopted with approval of  
169 the medical staff for the purpose of identifying those medicinal  
170 drugs, proprietary preparations, biologics, biosimilars, and  
171 biosimilar interchangeables that may be dispensed by the  
172 pharmacists employed in such institution. A facility with a  
173 Class II or Class III institutional pharmacy permit which is  
174 operating under the formulary system shall establish policies

22-00467E-18

20181128\_\_

175 and procedures for the development of the system in accordance  
176 with the joint standards of the American Hospital Association  
177 and American Society of Hospital Pharmacists for the utilization  
178 of a hospital formulary system, which formulary shall be  
179 approved by the medical staff.

180 Section 4. Subsection (3) of section 465.0252, Florida  
181 Statutes, is amended to read:

182 465.0252 Substitution of interchangeable biosimilar  
183 products.—

184 (3) A pharmacist who practices in a Class II, ~~or~~ modified  
185 Class II, or Class III institutional pharmacy shall comply with  
186 the notification provisions of paragraph (2)(c) by entering the  
187 substitution in the institution's written medical record system  
188 or electronic medical record system.

189 Section 5. Subsection (39) of section 499.003, Florida  
190 Statutes, is amended to read:

191 499.003 Definitions of terms used in this part.—As used in  
192 this part, the term:

193 (39) "Prepackaged drug product" means a drug that  
194 originally was in finished packaged form sealed by a  
195 manufacturer and that is placed in a properly labeled container  
196 by a pharmacy or practitioner authorized to dispense pursuant to  
197 chapter 465 ~~for the purpose of dispensing in the establishment~~  
198 ~~in which the prepackaging occurred.~~

199 Section 6. Paragraphs (b) and (h) of subsection (2) and  
200 subsection (5) of section 499.01, Florida Statutes, are amended  
201 to read:

202 499.01 Permits.—

203 (2) The following permits are established:

22-00467E-18

20181128\_\_

204 (b) *Prescription drug repackager permit.*—A prescription  
 205 drug repackager permit is required for any person that  
 206 repackages a prescription drug in this state.

207 1. A person that operates an establishment permitted as a  
 208 prescription drug repackager may engage in distribution of  
 209 prescription drugs repackaged at that establishment and must  
 210 comply with all of the provisions of this part and the rules  
 211 adopted under this part that apply to a prescription drug  
 212 manufacturer.

213 2. A prescription drug repackager must comply with all  
 214 appropriate state and federal good manufacturing practices.

215 3. A prescription drug repackager permit is not required  
 216 for the distribution of medicinal drugs or prepackaged drug  
 217 products between entities under common control if each entity  
 218 holds an active Class III institutional pharmacy permit under  
 219 chapter 465 or an active health care clinic establishment permit  
 220 under paragraph (r). For purposes of this subparagraph, the term  
 221 “common control” means the same as in s. 465.019(2).

222 (h) *Restricted prescription drug distributor permit.*—

223 1. A restricted prescription drug distributor permit is  
 224 required for:

225 a. Any person located in this state who engages in the  
 226 distribution of a prescription drug, which distribution is not  
 227 considered “wholesale distribution” under s. 499.003(48)(a).

228 b. Any person located in this state who engages in the  
 229 receipt or distribution of a prescription drug in this state for  
 230 the purpose of processing its return or its destruction if such  
 231 person is not the person initiating the return, the prescription  
 232 drug wholesale supplier of the person initiating the return, or

22-00467E-18

20181128\_\_

233 the manufacturer of the drug.

234 c. A blood establishment located in this state which  
235 collects blood and blood components only from volunteer donors  
236 as defined in s. 381.06014 or pursuant to an authorized  
237 practitioner's order for medical treatment or therapy and  
238 engages in the wholesale distribution of a prescription drug not  
239 described in s. 499.003(48)(j) to a health care entity. A mobile  
240 blood unit operated by a blood establishment permitted under  
241 this sub-subparagraph is not required to be separately  
242 permitted. The health care entity receiving a prescription drug  
243 distributed under this sub-subparagraph must be licensed as a  
244 closed pharmacy or provide health care services at that  
245 establishment. The blood establishment must operate in  
246 accordance with s. 381.06014 and may distribute only:

247 (I) Prescription drugs indicated for a bleeding or clotting  
248 disorder or anemia;

249 (II) Blood-collection containers approved under s. 505 of  
250 the federal act;

251 (III) Drugs that are blood derivatives, or a recombinant or  
252 synthetic form of a blood derivative;

253 (IV) Prescription drugs that are identified in rules  
254 adopted by the department and that are essential to services  
255 performed or provided by blood establishments and authorized for  
256 distribution by blood establishments under federal law; or

257 (V) To the extent authorized by federal law, drugs  
258 necessary to collect blood or blood components from volunteer  
259 blood donors; for blood establishment personnel to perform  
260 therapeutic procedures under the direction and supervision of a  
261 licensed physician; and to diagnose, treat, manage, and prevent

22-00467E-18

20181128\_\_

262 any reaction of a volunteer blood donor or a patient undergoing  
263 a therapeutic procedure performed under the direction and  
264 supervision of a licensed physician,  
265  
266 as long as all of the health care services provided by the blood  
267 establishment are related to its activities as a registered  
268 blood establishment or the health care services consist of  
269 collecting, processing, storing, or administering human  
270 hematopoietic stem cells or progenitor cells or performing  
271 diagnostic testing of specimens if such specimens are tested  
272 together with specimens undergoing routine donor testing. The  
273 blood establishment may purchase and possess the drugs described  
274 in this sub-subparagraph without a health care clinic  
275 establishment permit.

276 2. Storage, handling, and recordkeeping of these  
277 distributions by a person required to be permitted as a  
278 restricted prescription drug distributor must be in accordance  
279 with the requirements for wholesale distributors under s.  
280 499.0121.

281 3. A person who applies for a permit as a restricted  
282 prescription drug distributor, or for the renewal of such a  
283 permit, must provide to the department the information required  
284 under s. 499.012.

285 4. The department may adopt rules regarding the  
286 distribution of prescription drugs by hospitals, health care  
287 entities, charitable organizations, other persons not involved  
288 in wholesale distribution, and blood establishments, which rules  
289 are necessary for the protection of the public health, safety,  
290 and welfare.

22-00467E-18

20181128\_\_

291           5. A restricted prescription drug distributor permit is not  
292 required for distributions between pharmacies that each hold an  
293 active permit under chapter 465, have a common ownership, and  
294 are operating in a freestanding end-stage renal dialysis clinic,  
295 if such distributions are made to meet the immediate emergency  
296 medical needs of specifically identified patients and do not  
297 occur with such frequency as to amount to the regular and  
298 systematic supplying of that drug between the pharmacies. The  
299 department shall adopt rules establishing when the distribution  
300 of a prescription drug under this subparagraph amounts to the  
301 regular and systematic supplying of that drug.

302           6. A restricted prescription drug distributor permit is not  
303 required for the distribution of medicinal drugs or prepackaged  
304 drug products between entities under common control if each  
305 entity holds an active Class III institutional pharmacy permit  
306 under chapter 465 or an active health care clinic establishment  
307 permit under paragraph (r). For purposes of this subparagraph,  
308 the term "common control" means the same as in s. 465.019(2).

309           7. A restricted prescription drug distributor permit is not  
310 required for a hospital covered by s. 340B of the Public Health  
311 Service Act, 42 U.S.C. s. 256b, if such hospital arranges for a  
312 prescription drug wholesale distributor to distribute  
313 prescription drugs covered under that act directly to a contract  
314 pharmacy.

315           ~~(5) A prescription drug repackager permit issued under this~~  
316 ~~part is not required for a restricted prescription drug~~  
317 ~~distributor permitholder that is a health care entity to~~  
318 ~~repackage prescription drugs in this state for its own use or~~  
319 ~~for distribution to hospitals or other health care entities in~~

22-00467E-18

20181128\_\_

320 ~~the state for their own use, pursuant to s. 499.003(48)(a)3.,~~  
321 ~~if:~~

322 ~~(a) The prescription drug distributor notifies the~~  
323 ~~department, in writing, of its intention to engage in~~  
324 ~~repackaging under this exemption, 30 days before engaging in the~~  
325 ~~repackaging of prescription drugs at the permitted~~  
326 ~~establishment;~~

327 ~~(b) The prescription drug distributor is under common~~  
328 ~~control with the hospitals or other health care entities to~~  
329 ~~which the prescription drug distributor is distributing~~  
330 ~~prescription drugs. As used in this paragraph, "common control"~~  
331 ~~means the power to direct or cause the direction of the~~  
332 ~~management and policies of a person or an organization, whether~~  
333 ~~by ownership of stock, voting rights, contract, or otherwise;~~

334 ~~(c) The prescription drug distributor repackages the~~  
335 ~~prescription drugs in accordance with current state and federal~~  
336 ~~good manufacturing practices; and~~

337 ~~(d) The prescription drug distributor labels the~~  
338 ~~prescription drug it repackages in accordance with state and~~  
339 ~~federal laws and rules.~~

340  
341 ~~The prescription drug distributor is exempt from the product~~  
342 ~~registration requirements of s. 499.015 with regard to the~~  
343 ~~prescription drugs that it repackages and distributes under this~~  
344 ~~subsection. A prescription drug distributor that repackages and~~  
345 ~~distributes prescription drugs under this subsection to a not-~~  
346 ~~for-profit rural hospital, as defined in s. 395.602, is not~~  
347 ~~required to comply with paragraph (c) or paragraph (d), but must~~  
348 ~~provide to each health care entity for which it repackages, for~~

22-00467E-18

20181128\_\_

349 ~~each prescription drug that is repackaged and distributed, the~~  
350 ~~information required by department rule for labeling~~  
351 ~~prescription drugs. The department shall adopt rules to ensure~~  
352 ~~the safety and integrity of prescription drugs repackaged and~~  
353 ~~distributed under this subsection, including rules regarding~~  
354 ~~prescription drug manufacturing and labeling requirements.~~

355 Section 7. This act shall take effect July 1, 2018.